Agendia, CBLPath Collaborate on Breast Cancer MDx | GenomeWeb

NEW YORK (GenomeWeb) – Agendia and CBLPath today announced a collaboration to provide molecular diagnostic testing to breast cancer patients.

CBLPath provides pathology services with a large focus on breast cancer, Agendia CMO Neil Barth said, while his firm offers the MammaPrint test for breast cancer recurrence and the BluePrint assay for molecular subtyping of breast cancer. "By working closely together, Agendia and CBLPath will move the treatment of breast cancer toward better outcomes and fewer unnecessary side effects," he said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.